Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 12, 2007, Pages 4630-4636

  Dawson Hughes, Bess ^a   Chen, Peiqi ^b   Krege, John H ^b  

^a TUFTS UNIVERSITY   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; BIOLOGICAL MARKER; CALCIUM; PARATHYROID HORMONE[1-34]; PLACEBO; PROCOLLAGEN C PROTEINASE; VITAMIN D;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; BONE DENSITY; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; FEMUR NECK; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSSIFICATION; OUTCOME ASSESSMENT; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RANDOMIZATION; RISK ASSESSMENT; TREATMENT DURATION; TREATMENT RESPONSE; VERTEBRA DISLOCATION; VITAMIN D DEFICIENCY;

EID: 36849053926     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2007-0239     Document Type: Article

References (35)

1. Kinyamu HK, Gallagher JC, Balhorn KE, Petranick KM, Rafferty KA 1997 Serum vitamin D metabolites and calcium absorption in normal young and elderly free-living women and in women living in nursing homes. Am J Clin Nutr 65:790-797
2. Aaron JE, Gallagher JC, Anderson J, Stasiak L, Longton EB, Nordin BE, Nicholson M 1974 Frequency of osteomalacia and osteoporosis in fractures of the proximal femur. Lancet 1:229-233
3. Holick MF 2004 Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 79:362-371
4. Malabanan A, Veronikis IE, Holick MF 1998 Redefining vitamin D insufficiency. Lancet 351:805-806
5. Bischoff-Ferrari HA, Dietrich T, Orav EJ, Hu FB, Zhang Y, Karlson EW, Dawson-Hughes B 2004 Higher 25-hydroxyvitamin D concentrations are associated with better lower-extremity function in both active and inactive persons aged ≥60 y. Am J Clin Nutr 80:752-758
6. Gass M, Dawson-Hughes B 2006 Preventing osteoporosis-related fractures: on overview. Am J Med 119:3S-11S
7. Bettica P, Bevilacqua M, Vago T, Norbiato G 1999 High prevalence of hypovitaminosis D among free-living postmenopausal women referred to an osteoporosis outpatient clinic in northern Italy for initial screening. Osteoporos Int 9:226-229
8. Aguado P, del Campo MT, Garces MV, Gonzalez-Casaus ML, Bernad M, Gijon-Banos J, Martin Mola E, Torrijos A, Martinez ME 2000 Low vitamin D levels in outpatient postmenopausal women from a rheumatology clinic in Madrid, Spain: their relationship with bone mineral density. Osteoporos Int 11:739-744
9. Chapuy MC, Schott AM, Garnero P, Hans D, Delmas PD, Meunier PJ 1996 Healthy elderly French women living at home have secondary hyperparathyroidism and high bone turnover in winter. EPIDOS Study Group. J Clin Endocrinol Metab 81:1129-1133
10. Holick MF, Siris ES, Binkley N, Beard MK, Khan A, Katzer JT, Petruschke RA, Chen E, de Papp AE 2005 Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 90:3215-3224
11. Holick MF 2006 The role of vitamin D for bone health and fracture prevention. Curr Osteoporos Rep 4:96-102
12. Koster JC, Hackeng WH, Mulder H 1996 Diminished effect of etidronate in vitamin D deficient osteopenic postmenopausal women. Eur J Clin Pharmacol 51:145-147
13. Antoniucci DM, Vittinghoff E, Blackwell T, Black DM, Sellmeyer DE 2005 Vitamin D insufficiency does not affect bone mineral density response to raloxifene. J Clin Endocrinol Metab 90:4566-4572
14. Antoniucci DM, Vittinghoff E, Palermo L, Black DM, Sellmeyer DE, The bone density effects of alendronate therapy, co-administered with calcium and ergocalciferol, are not impaired by baseline vitamin D insufficiency. Program of the 88th Annual Meeting of The Endocrine Society, Boston, MA, 2006, pp 520-521 (Abstract P2-498)
15. McClung MR, San Martin J, Miller PD, Civitelli R, Bandeira F, Omizo M, Donley DW, Dalsky GP, Eriksen EF 2005 Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med 165:1762-1768
16. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis.NEngl J Med 344:1434-1441
17. Genant HK, Wu CY, van Kuijk C, Nevitt MC 1993 Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137-1148
18. Eastell R, Chen P, Krege JH 2005 Monitoring teriparatide therapy for osteoporosis with procollagen type I N-propeptide (PINP). Curr Med Res Opin 22:61-68
19. Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Watman RB 2005 Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis. J Bone Miner Res 20:962-970
20. Vieth R, Chan PCR, MacFarlane GD 2001 Efficacy and safety of vitamin D3 intake exceeding the lowest observed adverse effect level. Am J Clin Nutr 73:288-294
21. Suzuki Y, Ishibashi Y, Omura N, Kawasaki N, Kashiwagi H, Yanaga K, Abo M, Urashima M 2005 Alendronate improves vitamin D-resistant osteopenia triggered by gastrectomy in patients with gastric cancer followed long term. J Gastrointest Surg 9:955-960
22. Lee P, Colman PG, Ebeling PR 2006 Higher serum 25(OH)D concentrations are related to larger BMD increases with alendronate therapy for osteoporosis. J Bone Miner Res 22(Suppl 1):T72
23. Heaney RP, Dowell MS, Hale CA, Bendich A 2003 Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 22:142-146
24. Chapuy MC, Preziosi P, Maamer M, Arnaud S, Galan P, Hercberg S, Meunier PJ 1997 Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 7:439-443
25. Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R 2005 Estimates of optimal vitamin D status. Osteoporos Int 16:713-716
26. Bell NH, Epstein S, Greene A, Shary J, Oexmann MJ, Shaw S 1985 Evidence for alteration of the vitamin D endocrine system in obese subjects. J Clin Invest 76:370-373
27. Thomas MK, Lloyd-Jones DM, Thadhani RI, Shaw AC, Deraska DJ, Kitch BT, Vamvakas EC, Dick IM, Prince RL, Finkelstein JS 1998 Hypovitaminosis D in medical inpatients. N Engl J Med 338:777-783
28. Saquib N, von Mühlen D, Garland CF, Barrett-Connor E 2006 Serum 25-hydroxyvitamin D, parathyroid hormone, and bone mineral density in men: the Rancho Bernardo study. Osteoporosis Int 17:1734-1741
29. Bolland MJ, Grey AB, Ames RW, Horne AM, Gamble GD, Reid IR 2006 Fat mass is an important predictor of parathyroid hormone levels in postmenopausal women. Bone 38:317-321
30. Pettifor JM 2006 Nutritional and drug-induced rickets and osteomalacia. In: Favus M, ed. Primer on the metabolic bone diseases and disorders of mineral metabolism. 6th ed. Washington, DC: American Society of Bone and Mineral Research; 330-338
31. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ 2003 Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr 77:204-210
32. Lips P, Chapuy MC, Dawson-Hughes B, Pols HA, Holick MF 1999 An international comparison of serum 25-hydroxyvitamin D measurements. Osteoporos Int 9:394-397
33. Binkley N, Krueger D, Cowgill CS, Plum L, Lake E, Hansen KE, DeLuca HF, Drezner MK 2004 Assay variation confounds the diagnosis of hypovitaminosis D: a call for standardization. J Clin Endocrinol Metab 89:3152-3157
34. Gemar DM, Binkley N, Krueger D, Engelke J, Drezner MK 2004 Clinical assessment of vitamin D status: an imposing dilemma. J Bone Miner Res 19(Suppl 1):S343
35. 125I-labeled tracer. Clin Chem 39:529-533